MiMARK Diagnostics, S.L. successfully Closes First Seed Round with €4.22 Million to Impact on Gynecological Diagnostics

MiMARK Diagnostics, S.L. a pioneering femtech spin-off from the Vall d'Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage. The substantial investment will drive the development of the company's groundbreaking gynecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Council) and private investors, including Clave Capital, Nara Capital, Namarel Ventures, and WA4STEAM investing in May this year, and CDTI Innvierte, Inveready and Canterbury Scientific, joining later on.

Marina Rigau, CEO and co-founder of MiMARK, expressed gratitude for the support received, stating,
"This seed funding represents a significant milestone for MiMARK and validates our commitment to
improve gynecological diagnostics. Thanks to this funding we will advance on bringing our first product
to the market; an In Vitro Diagnostic for Endometrial Cancer. We are excited about the journey ahead
and the positive impact our innovations will have on women's health."

Key Highlights:

Amount Raised: MiMARK Diagnostics, S.L. secured a substantial €4.22 million in funding, highlighting the confidence and interest in the company's innovative approach to gynecological diagnostics.

Key Private Investors: Private investors who lead a first closing in May this year were: Clave Capital, Nara Capital, and Namarel Ventures, together with WA4STEAM. Later, CDTI Innvierte, Inveready, and Canterbury Scientific, joined the seed round, which was finally closed on November 3rd. This diverse group of investors further strengthens the network of supporters backing MiMARK's vision

Public funding raised: The seed funding saw significant participation from the EIC Accelerator, with a total amount of 2.5 million, an initiative of the European Innovation Council dedicated to supporting innovative startups and SMEs.

Achievements and Milestones: MiMARK Diagnostics has achieved noteworthy milestones in the development of its flagship product, WomEC—an in vitro diagnostic test for endometrial cancer.

WomEC is now in the last stage of prototyping and will move to the verification and validation
stages thanks to current fundraising.

Future Plans:
The newly secured funds will be instrumental in advancing MiMARK Diagnostics' mission to transform
gynecological diagnostics, and especially to advance the first product to the market. Future plans include:

- Accelerating verification and clinical validation for WomEC; an IVD for endometrial cancer diagnosis.

- Expanding research and development efforts to address other unmet clinical needs in gynecological health, with a focus on leveraging gynecological fluids as a source of biomarkers. A second target indication for the company is endometriosis diagnosis.

- Strengthening collaborations with leading institutions, healthcare professionals, and industry partners to further advance the field of gynecological diagnostics.

MiMARK Diagnostics, S.L. remains committed to improving women's health through innovation and
scientific excellence.

For more information about MiMARK Diagnostics, S.L. visit MiMARK Diagnostics Website.

https://www.mimark.es/